4.50
Schlusskurs vom Vortag:
$4.52
Offen:
$4.51
24-Stunden-Volumen:
1.80M
Relative Volume:
1.28
Marktkapitalisierung:
$1.73B
Einnahmen:
$775.09M
Nettoeinkommen (Verlust:
$-58.68M
KGV:
-33.94
EPS:
-0.1326
Netto-Cashflow:
$64.06M
1W Leistung:
-3.02%
1M Leistung:
-9.64%
6M Leistung:
-34.31%
1J Leistung:
-36.62%
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Vergleichen Sie GDRX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
GDRX
Goodrx Holdings Inc
|
4.50 | 1.73B | 775.09M | -58.68M | 64.06M | -0.1326 |
![]()
VEEV
Veeva Systems Inc
|
234.21 | 38.81B | 2.75B | 714.14M | 1.09B | 4.33 |
![]()
SOLV
Solventum Corp
|
74.75 | 12.84B | 8.26B | 66.00M | 1.17B | 0.3682 |
![]()
DOCS
Doximity Inc
|
58.51 | 11.36B | 516.85M | 174.11M | 217.38M | 0.87 |
![]()
TEM
Tempus Ai Inc
|
47.83 | 10.16B | 640.44M | -743.28M | -206.93M | -11.29 |
![]()
HQY
Healthequity Inc
|
86.96 | 7.54B | 1.15B | 96.70M | -161.99M | 1.09 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-04 | Eingeleitet | Mizuho | Neutral |
2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
2022-12-01 | Eingeleitet | Citigroup | Buy |
2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
2022-09-07 | Eingeleitet | Truist | Hold |
2022-08-12 | Eingeleitet | DA Davidson | Neutral |
2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
2022-06-06 | Fortgesetzt | BofA Securities | Buy |
2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
2022-04-07 | Eingeleitet | Guggenheim | Buy |
2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2022-03-01 | Bestätigt | Barclays | Overweight |
2022-03-01 | Bestätigt | BofA Securities | Neutral |
2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
2022-03-01 | Bestätigt | Evercore ISI | Outperform |
2022-03-01 | Bestätigt | Goldman | Buy |
2022-03-01 | Bestätigt | JP Morgan | Underweight |
2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
2022-03-01 | Bestätigt | SVB Leerink | Outperform |
2022-01-07 | Eingeleitet | Goldman | Buy |
2021-12-21 | Eingeleitet | Stephens | Overweight |
2021-12-02 | Eingeleitet | Jefferies | Buy |
2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
2021-01-25 | Eingeleitet | Guggenheim | Buy |
2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-10-19 | Eingeleitet | Barclays | Equal Weight |
2020-10-19 | Eingeleitet | BofA Securities | Neutral |
2020-10-19 | Eingeleitet | Citigroup | Buy |
2020-10-19 | Eingeleitet | Cowen | Outperform |
2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
2020-10-19 | Eingeleitet | Goldman | Neutral |
2020-10-19 | Eingeleitet | JP Morgan | Neutral |
2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
Levi & Korsinsky Notifies GoodRx Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineGDRX - ACCESS Newswire
GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital - Yahoo Finance
Do Fundamentals Have Any Role To Play In Driving GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Stock Up Recently? - Simply Wall St
GoodRx: Great Value For Patient Investors (Upgrade) (NASDAQ:GDRX) - Seeking Alpha
PBMs Hit With Antitrust Suit Over GoodRx Generics Program - Law360
GoodRx Strengthens Leadership: $100M Revenue Leader Takes President Role - StockTitan
GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Sold by US Bancorp DE - Defense World
GoodRx Holdings, Inc. (GDRX): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock? - Insider Monkey
GoodRx Holdings, Inc. (GDRX): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
12 Cash-Rich Penny Stocks To Buy According To Hedge Funds - Insider Monkey
Shareholders of GoodRx Holdings, Inc. Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your RightsGDRX - ACCESS Newswire
Investors in GoodRx Holdings, Inc. Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your RightsGDRX - ACCESS Newswire
Wells Fargo & Company Cuts GoodRx (NASDAQ:GDRX) Price Target to $8.00 - Defense World
Levi & Korsinsky Notifies Shareholders of GoodRx Holdings, Inc.(GDRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
GoodRx Holdings, Inc. (GDRX) Q4 Earnings Match Estimates - MSN
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q4 2024 Earnings Call Transcript - MSN
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GoodRx Holdings, Inc.(GDRX) Shareholders - ACCESS Newswire
The Analyst Verdict: GoodRx Holdings In The Eyes Of 4 Experts - Benzinga
Investors who lost money on GoodRx Holdings, Inc.(GDRX) should contact Levi & Korsinsky about pending Class ActionGDRX - ACCESS Newswire
GoodRx Holdings Leads The Charge With These 3 Promising Penny Stocks - Simply Wall St
Decoding GoodRx Holdings Inc (GDRX): A Strategic SWOT Insight - GuruFocus.com
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales - Benzinga India
GoodRx Holdings Inc (GDRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
GoodRx Holdings Reports Strong 2024 Financial Results - TipRanks
GoodRx Earnings Call: Growth Amid Challenges - TipRanks
Citi raises GoodRx stock target to $6.75, maintains buy rating By Investing.com - Investing.com South Africa
GoodRx Holdings IncOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire
Citi raises GoodRx stock target to $6.75, maintains buy rating - Investing.com
Insights Into GoodRx (GDRX) Q4: Wall Street Projections for Key Metrics - MSN
Raymond James Reiterates Strong Buy Rating on GoodRx Holdings Inc. (GDRX) - StreetInsider.com
GoodRx Holdings Inc. (GDRX) PT Raised to $6.75 at Citi - StreetInsider.com
GoodRx shares rise on upbeat Q1 guidance despite Q4 miss By Investing.com - Investing.com Australia
Earnings call transcript: GoodRx Q4 2024 misses EPS forecast, stock rises - Investing.com
GoodRx Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Here's What Key Metrics Tell Us About GoodRx (GDRX) Q4 Earnings - Yahoo Finance
GoodRx Q4 Adjusted Earnings, Revenue Rise; Q1, 2025 Revenue Guidance Issued - Marketscreener.com
GoodRx Reports Fourth Quarter and Full Year 2024 Results - 01Net
GoodRx Holdings Sees Increased Revenue In Q1, Full YearUpdate - Nasdaq
GOODRX Earnings Results: $GDRX Reports Quarterly Earnings - Nasdaq
BRIEF-GoodRx Holdings Q4 Adjusted Net Income USD 34.7 Million Vs. IBES Estimate USD 37.4 Million - TradingView
GoodRx Holdings, Inc. (GDRX) Misses Q4 EPS by 1c ; Offers Guidance - StreetInsider.com
GoodRx Earnings: What To Look For From GDRX By Stock Story - Investing.com Canada
GoodRx Earnings: What To Look For From GDRX - The Globe and Mail
GoodRx Holdings Inc (GDRX) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
GoodRx’s SWOT analysis: prescription savings leader faces pharmacy headwinds - Investing.com
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):